-
1
-
-
84858766182
-
The blockade of immune checkpoints in cancer immunotherapy
-
COI: 1:CAS:528:DC%2BC38XksVegtrw%3D, PID: 22437870
-
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.
-
(2012)
Nat Rev Cancer
, vol.12
, Issue.4
, pp. 252-264
-
-
Pardoll, D.M.1
-
2
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
COI: 1:CAS:528:DC%2BC3cXhtVCrtrbN, PID: 20525992
-
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.
-
(2010)
N Engl J Med
, vol.363
, Issue.8
, pp. 711-723
-
-
Hodi, F.S.1
O’Day, S.J.2
McDermott, D.F.3
Weber, R.W.4
Sosman, J.A.5
Haanen, J.B.6
-
3
-
-
84936147067
-
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
-
PID: 26027431
-
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.
-
(2015)
N Engl J Med
, vol.373
, Issue.1
, pp. 23-34
-
-
Larkin, J.1
Chiarion-Sileni, V.2
Gonzalez, R.3
Grob, J.J.4
Cowey, C.L.5
Lao, C.D.6
-
4
-
-
84936791837
-
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
-
COI: 1:CAS:528:DC%2BC2MXht12qu7%2FJ, PID: 26028407
-
Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35.
-
(2015)
N Engl J Med
, vol.373
, Issue.2
, pp. 123-135
-
-
Brahmer, J.1
Reckamp, K.L.2
Baas, P.3
Crino, L.4
Eberhardt, W.E.5
Poddubskaya, E.6
-
5
-
-
84929481481
-
Pembrolizumab versus ipilimumab in advanced melanoma
-
COI: 1:CAS:528:DC%2BC2MXhtFyrsbrF, PID: 25891173
-
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32.
-
(2015)
N Engl J Med
, vol.372
, Issue.26
, pp. 2521-2532
-
-
Robert, C.1
Schachter, J.2
Long, G.V.3
Arance, A.4
Grob, J.J.5
Mortier, L.6
-
6
-
-
84963621254
-
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
-
COI: 1:CAS:528:DC%2BC28XmtVOrurc%3D, PID: 27079802
-
Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275–87.
-
(2016)
Nat Rev Cancer
, vol.16
, Issue.5
, pp. 275-287
-
-
Topalian, S.L.1
Taube, J.M.2
Anders, R.A.3
Pardoll, D.M.4
-
7
-
-
85017789541
-
An important study that examined the frequency of and relationships between predictive biomarkers for immune checkpoint blockade efficacy in glioma. High tumor mutational burden was found to occur infrequently but was associated with MMR-deficiency. There was no significant between high mutation burden and CD8 TIL density or PD-L1 expression
-
Hodges TR, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S, et al
-
Hodges TR, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S, et al. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol. 2017. An important study that examined the frequency of and relationships between predictive biomarkers for immune checkpoint blockade efficacy in glioma. High tumor mutational burden was found to occur infrequently but was associated with MMR-deficiency. There was no significant between high mutation burden and CD8 TIL density or PD-L1 expression.
-
(2017)
Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol
-
-
-
8
-
-
85006987606
-
Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM
-
370ra180
-
Mathios D, Kim JE, Mangraviti A, Phallen J, Park CK, Jackson CM, et al. Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. Sci Transl Med. 8(370):370ra180.
-
Sci Transl Med
, vol.8
, Issue.370
-
-
Mathios, D.1
Kim, J.E.2
Mangraviti, A.3
Phallen, J.4
Park, C.K.5
Jackson, C.M.6
-
9
-
-
84962218955
-
Systemic tolerance mediated by melanoma brain tumors is reversible by radiotherapy and vaccination
-
COI: 1:CAS:528:DC%2BC28XktVykur4%3D, PID: 26490306
-
Jackson CM, Kochel CM, Nirschl CJ, Durham NM, Ruzevick J, Alme A, et al. Systemic tolerance mediated by melanoma brain tumors is reversible by radiotherapy and vaccination. Clin Cancer Res. 2016;22(5):1161–72.
-
(2016)
Clin Cancer Res
, vol.22
, Issue.5
, pp. 1161-1172
-
-
Jackson, C.M.1
Kochel, C.M.2
Nirschl, C.J.3
Durham, N.M.4
Ruzevick, J.5
Alme, A.6
-
10
-
-
0034596948
-
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
-
COI: 1:CAS:528:DC%2BD3cXntFSlt7o%3D, PID: 11015443
-
Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–34.
-
(2000)
J Exp Med
, vol.192
, Issue.7
, pp. 1027-1034
-
-
Freeman, G.J.1
Long, A.J.2
Iwai, Y.3
Bourque, K.4
Chernova, T.5
Nishimura, H.6
-
11
-
-
5844264920
-
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
-
COI: 1:CAS:528:DC%2BD3MXhvVaksrc%3D, PID: 11224527
-
Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2(3):261–8.
-
(2001)
Nat Immunol
, vol.2
, Issue.3
, pp. 261-268
-
-
Latchman, Y.1
Wood, C.R.2
Chernova, T.3
Chaudhary, D.4
Borde, M.5
Chernova, I.6
-
12
-
-
57849168934
-
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
-
COI: 1:CAS:528:DC%2BD1cXhsVenu73N, PID: 19043418
-
Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009;10(1):29–37.
-
(2009)
Nat Immunol
, vol.10
, Issue.1
, pp. 29-37
-
-
Blackburn, S.D.1
Shin, H.2
Haining, W.N.3
Zou, T.4
Workman, C.J.5
Polley, A.6
-
13
-
-
84937837169
-
Molecular and cellular insights into T cell exhaustion
-
COI: 1:CAS:528:DC%2BC2MXht1ensLvE, PID: 26205583
-
Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486–99.
-
(2015)
Nat Rev Immunol
, vol.15
, Issue.8
, pp. 486-499
-
-
Wherry, E.J.1
Kurachi, M.2
-
14
-
-
84994802263
-
Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer
-
COI: 1:CAS:528:DC%2BC28XhvF2ks77I, PID: 27718847
-
Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33.
-
(2016)
N Engl J Med
, vol.375
, Issue.19
, pp. 1823-1833
-
-
Reck, M.1
Rodriguez-Abreu, D.2
Robinson, A.G.3
Hui, R.4
Csoszi, T.5
Fulop, A.6
-
15
-
-
84946607195
-
Nivolumab versus everolimus in advanced renal-cell carcinoma
-
COI: 1:CAS:528:DC%2BC28XjsFyhsrg%3D, PID: 26406148
-
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13.
-
(2015)
N Engl J Med
, vol.373
, Issue.19
, pp. 1803-1813
-
-
Motzer, R.J.1
Escudier, B.2
McDermott, D.F.3
George, S.4
Hammers, H.J.5
Srinivas, S.6
-
16
-
-
84929342210
-
Antagonists of PD-1 and PD-L1 in cancer treatment
-
COI: 1:CAS:528:DC%2BC2MXhsV2mur3I, PID: 26320063
-
Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL. Antagonists of PD-1 and PD-L1 in cancer treatment. Semin Oncol. 2015;42(4):587–600.
-
(2015)
Semin Oncol
, vol.42
, Issue.4
, pp. 587-600
-
-
Lipson, E.J.1
Forde, P.M.2
Hammers, H.J.3
Emens, L.A.4
Taube, J.M.5
Topalian, S.L.6
-
17
-
-
20044366163
-
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
-
COI: 1:CAS:528:DC%2BD2MXit1Wksbk%3D, PID: 15758009
-
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.
-
(2005)
N Engl J Med
, vol.352
, Issue.10
, pp. 987-996
-
-
Stupp, R.1
Mason, W.P.2
van den Bent, M.J.3
Weller, M.4
Fisher, B.5
Taphoorn, M.J.6
-
18
-
-
85026898865
-
Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): updated results from checkmate-143
-
Reardon DA, Sampson JH, Sahebjam S, Lim M, Baehring JM, Vlahovic G, et al. Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): updated results from checkmate-143. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2016;34(suppl; abstr 2014).
-
(2014)
Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2016;34(suppl; abstr
-
-
Reardon, D.A.1
Sampson, J.H.2
Sahebjam, S.3
Lim, M.4
Baehring, J.M.5
Vlahovic, G.6
-
19
-
-
85007295572
-
Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease
-
COI: 1:CAS:528:DC%2BC28XitVGnt7zO, PID: 27663893
-
Liu J, Blake SJ, Yong MC, Harjunpaa H, Ngiow SF, Takeda K, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 2016;6(12):1382–99.
-
(2016)
Cancer Discov
, vol.6
, Issue.12
, pp. 1382-1399
-
-
Liu, J.1
Blake, S.J.2
Yong, M.C.3
Harjunpaa, H.4
Ngiow, S.F.5
Takeda, K.6
-
20
-
-
27144496045
-
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
-
COI: 1:CAS:528:DC%2BD2MXhtFOns77N, PID: 16227604
-
Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25(21):9543–53.
-
(2005)
Mol Cell Biol
, vol.25
, Issue.21
, pp. 9543-9553
-
-
Parry, R.V.1
Chemnitz, J.M.2
Frauwirth, K.A.3
Lanfranco, A.R.4
Braunstein, I.5
Kobayashi, S.V.6
-
21
-
-
84883192286
-
Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas
-
COI: 1:CAS:528:DC%2BC3sXhtlGnu7zJ, PID: 23737488
-
Xu S, Shao QQ, Sun JT, Yang N, Xie Q, Wang DH, et al. Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas. Neuro-Oncology. 2013;15(9):1160–72.
-
(2013)
Neuro-Oncology
, vol.15
, Issue.9
, pp. 1160-1172
-
-
Xu, S.1
Shao, Q.Q.2
Sun, J.T.3
Yang, N.4
Xie, Q.5
Wang, D.H.6
-
22
-
-
84904061991
-
Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors
-
COI: 1:CAS:528:DC%2BC2cXhslKnsr%2FK, PID: 24691018
-
Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim CK, Tobias A, et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res. 2014;20(20):5290–301.
-
(2014)
Clin Cancer Res
, vol.20
, Issue.20
, pp. 5290-5301
-
-
Wainwright, D.A.1
Chang, A.L.2
Dey, M.3
Balyasnikova, I.V.4
Kim, C.K.5
Tobias, A.6
-
23
-
-
85010297255
-
Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas
-
COI: 1:CAS:528:DC%2BC2sXhs1Wntg%3D%3D, PID: 27358487
-
Kim JE, Patel MA, Mangraviti A, Kim ES, Theodros D, Velarde E, et al. Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas. Clin Cancer Res. 2017;23(1):124–36.
-
(2017)
Clin Cancer Res
, vol.23
, Issue.1
, pp. 124-136
-
-
Kim, J.E.1
Patel, M.A.2
Mangraviti, A.3
Kim, E.S.4
Theodros, D.5
Velarde, E.6
-
24
-
-
0027285735
-
Inducible T cell antigen 4-1BB. Analysis of expression and function
-
COI: 1:CAS:528:DyaK3sXhsVGntLg%3D, PID: 7678621
-
Pollok KE, Kim YJ, Zhou Z, Hurtado J, Kim KK, Pickard RT, et al. Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol. 1993;150(3):771–81.
-
(1993)
J Immunol
, vol.150
, Issue.3
, pp. 771-781
-
-
Pollok, K.E.1
Kim, Y.J.2
Zhou, Z.3
Hurtado, J.4
Kim, K.K.5
Pickard, R.T.6
-
25
-
-
0031007143
-
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
-
Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med. 1997 Jun;3(6):682–5.
-
(1997)
Nat Med
, vol.3
, Issue.6
, pp. 682-685
-
-
Melero, I.1
Shuford, W.W.2
Newby, S.A.3
Aruffo, A.4
Ledbetter, J.A.5
Hellstrom, K.E.6
-
26
-
-
84904207094
-
Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model
-
PID: 25013914
-
Belcaid Z, Phallen JA, Zeng J, See AP, Mathios D, Gottschalk C, et al. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. PLoS One. 2014;9(7):e101764.
-
(2014)
PLoS One
, vol.9
, Issue.7
-
-
Belcaid, Z.1
Phallen, J.A.2
Zeng, J.3
See, A.P.4
Mathios, D.5
Gottschalk, C.6
-
27
-
-
84937517015
-
The role of IDO in brain tumor immunotherapy
-
COI: 1:CAS:528:DC%2BC2cXitFOrs7bO
-
Zhai L, Lauing KL, Chang AL, Dey M, Qian J, Cheng Y, et al. The role of IDO in brain tumor immunotherapy. J Neuro-Oncol. 2015;123(3):395–403.
-
(2015)
J Neuro-Oncol
, vol.123
, Issue.3
, pp. 395-403
-
-
Zhai, L.1
Lauing, K.L.2
Chang, A.L.3
Dey, M.4
Qian, J.5
Cheng, Y.6
-
28
-
-
0036790338
-
T cell apoptosis by tryptophan catabolism
-
COI: 1:CAS:528:DC%2BD38XmvFGhtbY%3D, PID: 12232795
-
Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A, et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 2002;9(10):1069–77.
-
(2002)
Cell Death Differ
, vol.9
, Issue.10
, pp. 1069-1077
-
-
Fallarino, F.1
Grohmann, U.2
Vacca, C.3
Bianchi, R.4
Orabona, C.5
Spreca, A.6
-
29
-
-
78649880396
-
An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells
-
COI: 1:CAS:528:DC%2BC3cXhtFSntL7F, PID: 20720200
-
Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol. 2010;185(6):3190–8.
-
(2010)
J Immunol
, vol.185
, Issue.6
, pp. 3190-3198
-
-
Mezrich, J.D.1
Fechner, J.H.2
Zhang, X.3
Johnson, B.P.4
Burlingham, W.J.5
Bradfield, C.A.6
-
30
-
-
84869232447
-
IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival
-
COI: 1:CAS:528:DC%2BC38Xhs12jur7I, PID: 22932670
-
Wainwright DA, Balyasnikova IV, Chang AL, Ahmed AU, Moon KS, Auffinger B, et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res. 2012;18(22):6110–21.
-
(2012)
Clin Cancer Res
, vol.18
, Issue.22
, pp. 6110-6121
-
-
Wainwright, D.A.1
Balyasnikova, I.V.2
Chang, A.L.3
Ahmed, A.U.4
Moon, K.S.5
Auffinger, B.6
-
31
-
-
85007439991
-
Dendritic cell-based immunotherapy
-
COI: 1:CAS:528:DC%2BC28XitFOhs7bM, PID: 28025976
-
Sabado RL, Balan S, Bhardwaj N. Dendritic cell-based immunotherapy. Cell Res. 2017;27(1):74–95.
-
(2017)
Cell Res
, vol.27
, Issue.1
, pp. 74-95
-
-
Sabado, R.L.1
Balan, S.2
Bhardwaj, N.3
-
32
-
-
85017141674
-
Tumor vaccines for malignant gliomas
-
COI: 1:CAS:528:DC%2BC2sXlvVKrsrg%3D, PID: 28389997
-
Srinivasan VM, Ferguson SD, Lee S, Weathers SP, Kerrigan BCP, Heimberger AB. Tumor vaccines for malignant gliomas. Neurotherapeutics. 2017;14(2):345–57.
-
(2017)
Neurotherapeutics
, vol.14
, Issue.2
, pp. 345-357
-
-
Srinivasan, V.M.1
Ferguson, S.D.2
Lee, S.3
Weathers, S.P.4
Kerrigan, B.C.P.5
Heimberger, A.B.6
-
33
-
-
85018815533
-
Dendritic cell based vaccination strategy: an evolving paradigm
-
Filley AC, Dey M. Dendritic cell based vaccination strategy: an evolving paradigm. J Neurooncol 2017 22.
-
(2017)
J Neurooncol
, vol.22
-
-
Filley, A.C.1
Dey, M.2
-
34
-
-
0035107548
-
Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration
-
COI: 1:CAS:528:DC%2BD3MXhsFSrtLs%3D, PID: 11221866, Feb 1
-
Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 2001 Feb 1;61(3):842–7.
-
(2001)
Cancer Res
, vol.61
, Issue.3
, pp. 842-847
-
-
Yu, J.S.1
Wheeler, C.J.2
Zeltzer, P.M.3
Ying, H.4
Finger, D.N.5
Lee, P.K.6
-
35
-
-
0242329784
-
Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial
-
COI: 1:CAS:528:DC%2BD3sXns1Cmu7k%3D, PID: 14520441
-
Yamanaka R, Abe T, Yajima N, Tsuchiya N, Homma J, Kobayashi T, et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer. 2003;89(7):1172–9.
-
(2003)
Br J Cancer
, vol.89
, Issue.7
, pp. 1172-1179
-
-
Yamanaka, R.1
Abe, T.2
Yajima, N.3
Tsuchiya, N.4
Homma, J.5
Kobayashi, T.6
-
36
-
-
3142692559
-
Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma
-
COI: 1:CAS:528:DC%2BD2cXls1Omt7o%3D, PID: 15256471
-
Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 2004;64(14):4973–9.
-
(2004)
Cancer Res
, vol.64
, Issue.14
, pp. 4973-4979
-
-
Yu, J.S.1
Liu, G.2
Ying, H.3
Yong, W.H.4
Black, K.L.5
Wheeler, C.J.6
-
37
-
-
79951978155
-
Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma
-
COI: 1:CAS:528:DC%2BC3MXit1yhurs%3D, PID: 21149657
-
Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011;29(3):330–6.
-
(2011)
J Clin Oncol
, vol.29
, Issue.3
, pp. 330-336
-
-
Okada, H.1
Kalinski, P.2
Ueda, R.3
Hoji, A.4
Kohanbash, G.5
Donegan, T.E.6
-
38
-
-
79952711945
-
Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy
-
COI: 1:CAS:528:DC%2BC3MXjtFCht7w%3D, PID: 21135147
-
Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res. 2011;17(6):1603–15.
-
(2011)
Clin Cancer Res
, vol.17
, Issue.6
, pp. 1603-1615
-
-
Prins, R.M.1
Soto, H.2
Konkankit, V.3
Odesa, S.K.4
Eskin, A.5
Yong, W.H.6
-
39
-
-
85071335009
-
PD-1 blockade enhances the vaccination-induced immune response in glioma
-
PID: 27453950
-
Antonios JP, Soto H, Everson RG, Orpilla J, Moughon D, Shin N, et al. PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight. 2016;1(10):e87059.
-
(2016)
JCI Insight
, vol.1
, Issue.10
-
-
Antonios, J.P.1
Soto, H.2
Everson, R.G.3
Orpilla, J.4
Moughon, D.5
Shin, N.6
-
40
-
-
85021790700
-
Autologous heat shock protein peptide vaccination for newly diagnosed glioblastoma: impact of peripheral PD-L1 expression on response to therapy
-
Bloch O, Lim M, Sughrue ME, Komotar RJ, Abrahams JM, O’Rourke DM, et al. Autologous heat shock protein peptide vaccination for newly diagnosed glioblastoma: impact of peripheral PD-L1 expression on response to therapy. Clin Cancer Res 2017 13.
-
(2017)
Clin Cancer Res
, vol.13
-
-
Bloch, O.1
Lim, M.2
Sughrue, M.E.3
Komotar, R.J.4
Abrahams, J.M.5
O’Rourke, D.M.6
-
41
-
-
85014550014
-
Oncolytic virotherapy for the treatment of malignant glioma
-
COI: 1:CAS:528:DC%2BC2sXjvVaiurg%3D, PID: 28265902
-
Foreman PM, Friedman GK, Cassady KA, Markert JM. Oncolytic virotherapy for the treatment of malignant glioma. Neurotherapeutics. 2017;14(2):333–44.
-
(2017)
Neurotherapeutics
, vol.14
, Issue.2
, pp. 333-344
-
-
Foreman, P.M.1
Friedman, G.K.2
Cassady, K.A.3
Markert, J.M.4
-
42
-
-
84883642231
-
Oncolytic viruses as therapeutic cancer vaccines
-
Bartlett DL, Liu Z, Sathaiah M, Ravindranathan R, Guo Z, He Y, et al. ;12(1):103. -4598-12-103
-
Bartlett DL, Liu Z, Sathaiah M, Ravindranathan R, Guo Z, He Y, et al. Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer. 2013;12(1):103. -4598-12-103
-
(2013)
Mol Cancer
-
-
-
43
-
-
34948820602
-
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
-
COI: 1:CAS:528:DC%2BD2sXhtVSgtr3E, PID: 17704786
-
Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050–9.
-
(2007)
Nat Med
, vol.13
, Issue.9
, pp. 1050-1059
-
-
Apetoh, L.1
Ghiringhelli, F.2
Tesniere, A.3
Obeid, M.4
Ortiz, C.5
Criollo, A.6
-
44
-
-
1242315588
-
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
-
PID: 14967443
-
Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004;58(3):862–70.
-
(2004)
Int J Radiat Oncol Biol Phys
, vol.58
, Issue.3
, pp. 862-870
-
-
Demaria, S.1
Ng, B.2
Devitt, M.L.3
Babb, J.S.4
Kawashima, N.5
Liebes, L.6
-
45
-
-
84983353116
-
Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen
-
COI: 1:CAS:528:DC%2BC2MXlvFemtLg%3D, PID: 25527358
-
Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francica BJ, Velarde E, et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res. 2015;3(4):345–55.
-
(2015)
Cancer Immunol Res
, vol.3
, Issue.4
, pp. 345-355
-
-
Sharabi, A.B.1
Nirschl, C.J.2
Kochel, C.M.3
Nirschl, T.R.4
Francica, B.J.5
Velarde, E.6
-
46
-
-
84893876109
-
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice
-
COI: 1:CAS:528:DC%2BC2cXis1ertbc%3D, PID: 24382348
-
Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687–95.
-
(2014)
J Clin Invest
, vol.124
, Issue.2
, pp. 687-695
-
-
Deng, L.1
Liang, H.2
Burnette, B.3
Beckett, M.4
Darga, T.5
Weichselbaum, R.R.6
-
47
-
-
84926525215
-
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
-
COI: 1:CAS:528:DC%2BC2MXktVCnsbw%3D, PID: 25754329
-
Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373–7.
-
(2015)
Nature
, vol.520
, Issue.7547
, pp. 373-377
-
-
Twyman-Saint Victor, C.1
Rech, A.J.2
Maity, A.3
Rengan, R.4
Pauken, K.E.5
Stelekati, E.6
-
48
-
-
84877581852
-
Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas
-
COI: 1:CAS:528:DC%2BC3sXivFyku7k%3D, PID: 23462419
-
Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86(2):343–9.
-
(2013)
Int J Radiat Oncol Biol Phys
, vol.86
, Issue.2
, pp. 343-349
-
-
Zeng, J.1
See, A.P.2
Phallen, J.3
Jackson, C.M.4
Belcaid, Z.5
Ruzevick, J.6
-
49
-
-
84887481716
-
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
-
COI: 1:CAS:528:DC%2BC3sXhsV2jsr3N, PID: 24056773
-
Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19(10):1264–72.
-
(2013)
Nat Med
, vol.19
, Issue.10
, pp. 1264-1272
-
-
Pyonteck, S.M.1
Akkari, L.2
Schuhmacher, A.J.3
Bowman, R.L.4
Sevenich, L.5
Quail, D.F.6
-
50
-
-
84943241524
-
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
-
PID: 25355681, An extensive biomarker study that analyzed TIL density and PD-L1 expression levels in GBM. PD-L1 gene expression was not found to be associated with OS
-
Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wohrer A, et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro-Oncology. 2015;17(8):1064–75. An extensive biomarker study that analyzed TIL density and PD-L1 expression levels in GBM. PD-L1 gene expression was not found to be associated with OS
-
(2015)
Neuro-Oncology
, vol.17
, Issue.8
, pp. 1064-1075
-
-
Berghoff, A.S.1
Kiesel, B.2
Widhalm, G.3
Rajky, O.4
Ricken, G.5
Wohrer, A.6
-
51
-
-
0029114319
-
Enhanced expression of transforming growth factor-beta and its type-I and type-II receptors in human glioblastoma
-
COI: 1:CAS:528:DyaK2MXpsVWms74%3D, PID: 7635563
-
Yamada N, Kato M, Yamashita H, Nister M, Miyazono K, Heldin CH, et al. Enhanced expression of transforming growth factor-beta and its type-I and type-II receptors in human glioblastoma. Int J Cancer. 1995;62(4):386–92.
-
(1995)
Int J Cancer
, vol.62
, Issue.4
, pp. 386-392
-
-
Yamada, N.1
Kato, M.2
Yamashita, H.3
Nister, M.4
Miyazono, K.5
Heldin, C.H.6
-
52
-
-
84946570713
-
TGF-beta signaling and its targeting for glioma treatment
-
COI: 1:CAS:528:DC%2BC28XhsFWlurnF, PID: 26045979
-
Han J, Alvarez-Breckenridge CA, Wang QE, Yu J. TGF-beta signaling and its targeting for glioma treatment. Am J Cancer Res. 2015;5(3):945–55.
-
(2015)
Am J Cancer Res
, vol.5
, Issue.3
, pp. 945-955
-
-
Han, J.1
Alvarez-Breckenridge, C.A.2
Wang, Q.E.3
Yu, J.4
-
53
-
-
84928761118
-
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
-
COI: 1:CAS:528:DC%2BC2MXls1Wmtbg%3D, PID: 25765070, A key clinical study that determined how tumor mutational burden impacts responses to anti-PD-1 therapy in NSCLC patients
-
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–8. A key clinical study that determined how tumor mutational burden impacts responses to anti-PD-1 therapy in NSCLC patients
-
(2015)
Science
, vol.348
, Issue.6230
, pp. 124-128
-
-
Rizvi, N.A.1
Hellmann, M.D.2
Snyder, A.3
Kvistborg, P.4
Makarov, V.5
Havel, J.J.6
-
54
-
-
84920956732
-
PD-1 blockade induces responses by inhibiting adaptive immune resistance
-
COI: 1:CAS:528:DC%2BC2cXitFanu7jL, PID: 25428505, Pivotal study demonstrating the association between the density of a pre-existing CD8 TIL infiltrate and therapeutic responses to pembrolizumab in melanoma patients
-
Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–71. Pivotal study demonstrating the association between the density of a pre-existing CD8 TIL infiltrate and therapeutic responses to pembrolizumab in melanoma patients
-
(2014)
Nature
, vol.515
, Issue.7528
, pp. 568-571
-
-
Tumeh, P.C.1
Harview, C.L.2
Yearley, J.H.3
Shintaku, I.P.4
Taylor, E.J.5
Robert, L.6
-
55
-
-
84962301577
-
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
-
COI: 1:CAS:528:DC%2BC28XksFCht70%3D, PID: 26940869
-
McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351(6280):1463–9.
-
(2016)
Science
, vol.351
, Issue.6280
, pp. 1463-1469
-
-
McGranahan, N.1
Furness, A.J.2
Rosenthal, R.3
Ramskov, S.4
Lyngaa, R.5
Saini, S.K.6
-
56
-
-
84880507665
-
Mutational heterogeneity in cancer and the search for new cancer-associated genes
-
COI: 1:CAS:528:DC%2BC3sXpsFSgsbo%3D, PID: 23770567
-
Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214–8.
-
(2013)
Nature
, vol.499
, Issue.7457
, pp. 214-218
-
-
Lawrence, M.S.1
Stojanov, P.2
Polak, P.3
Kryukov, G.V.4
Cibulskis, K.5
Sivachenko, A.6
-
57
-
-
84918828514
-
Genetic basis for clinical response to CTLA-4 blockade in melanoma
-
PID: 25409260
-
Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189–99.
-
(2014)
N Engl J Med
, vol.371
, Issue.23
, pp. 2189-2199
-
-
Snyder, A.1
Makarov, V.2
Merghoub, T.3
Yuan, J.4
Zaretsky, J.M.5
Desrichard, A.6
-
58
-
-
84932628341
-
PD-1 blockade in tumors with mismatch-repair deficiency
-
COI: 1:CAS:528:DC%2BC2MXhtFyrsbrI, PID: 26028255
-
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.
-
(2015)
N Engl J Med
, vol.372
, Issue.26
, pp. 2509-2520
-
-
Le, D.T.1
Uram, J.N.2
Wang, H.3
Bartlett, B.R.4
Kemberling, H.5
Eyring, A.D.6
-
59
-
-
84976467739
-
Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency
-
PID: 27001570
-
Bouffet E, Larouche V, Campbell BB, Merico D, de Borja R, Aronson M, et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol. 2016;34(19):2206–11.
-
(2016)
J Clin Oncol
, vol.34
, Issue.19
, pp. 2206-2211
-
-
Bouffet, E.1
Larouche, V.2
Campbell, B.B.3
Merico, D.4
de Borja, R.5
Aronson, M.6
-
60
-
-
84995511734
-
Immunogenomics of hypermutated glioblastoma: a patient with germline POLE deficiency treated with checkpoint blockade immunotherapy
-
PID: 27683556
-
Johanns TM, Miller CA, Dorward IG, Tsien C, Chang E, Perry A, et al. Immunogenomics of hypermutated glioblastoma: a patient with germline POLE deficiency treated with checkpoint blockade immunotherapy. Cancer Discov. 2016;6(11):1230–6.
-
(2016)
Cancer Discov
, vol.6
, Issue.11
, pp. 1230-1236
-
-
Johanns, T.M.1
Miller, C.A.2
Dorward, I.G.3
Tsien, C.4
Chang, E.5
Perry, A.6
-
61
-
-
84892373020
-
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma
-
COI: 1:CAS:528:DC%2BC2cXktVyktQ%3D%3D, PID: 24336570
-
Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343(6167):189–93.
-
(2014)
Science
, vol.343
, Issue.6167
, pp. 189-193
-
-
Johnson, B.E.1
Mazor, T.2
Hong, C.3
Barnes, M.4
Aihara, K.5
McLean, C.Y.6
-
62
-
-
84862859820
-
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
-
COI: 1:CAS:528:DC%2BC38XhtV2rs7fN, PID: 22658127, One of the first studies demonstrating the correlation between tumor PD-L1 expression and anti-PD-1 therapy efficacy. This was a phase 1 study that examined the safety and efficacy of nivolumab in multiple tumor types including advanced melanoma, NSCLC, castration-resistant prostate cancer, RCC, and colorectal canccer
-
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, DF MD, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54. One of the first studies demonstrating the correlation between tumor PD-L1 expression and anti-PD-1 therapy efficacy. This was a phase 1 study that examined the safety and efficacy of nivolumab in multiple tumor types including advanced melanoma, NSCLC, castration-resistant prostate cancer, RCC, and colorectal canccer
-
(2012)
N Engl J Med
, vol.366
, Issue.26
, pp. 2443-2454
-
-
Topalian, S.L.1
Hodi, F.S.2
Brahmer, J.R.3
Gettinger, S.N.4
Smith, D.C.5
Df, M.D.6
-
63
-
-
84929481480
-
Pembrolizumab for the treatment of non-small-cell lung cancer
-
PID: 25891174
-
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28.
-
(2015)
N Engl J Med
, vol.372
, Issue.21
, pp. 2018-2028
-
-
Garon, E.B.1
Rizvi, N.A.2
Hui, R.3
Leighl, N.4
Balmanoukian, A.S.5
Eder, J.P.6
-
64
-
-
84961618736
-
Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas
-
PID: 26771840
-
Zeng J, Zhang XK, Chen HD, Zhong ZH, Wu QL, Lin SX. Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas. Oncotarget. 2016;7(8):8944–55.
-
(2016)
Oncotarget
, vol.7
, Issue.8
, pp. 8944-8955
-
-
Zeng, J.1
Zhang, X.K.2
Chen, H.D.3
Zhong, Z.H.4
Wu, Q.L.5
Lin, S.X.6
-
65
-
-
84960407098
-
PD-L1 expression and prognostic impact in glioblastoma
-
PID: 26323609
-
Nduom EK, Wei J, Yaghi NK, Huang N, Kong LY, Gabrusiewicz K, et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro-Oncology. 2016;18(2):195–205.
-
(2016)
Neuro-Oncology
, vol.18
, Issue.2
, pp. 195-205
-
-
Nduom, E.K.1
Wei, J.2
Yaghi, N.K.3
Huang, N.4
Kong, L.Y.5
Gabrusiewicz, K.6
-
66
-
-
84994559117
-
Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma
-
PID: 27999734
-
Wang Z, Zhang C, Liu X, Wang Z, Sun L, Li G, et al. Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. Oncoimmunology. 2016;5(11):e1196310.
-
(2016)
Oncoimmunology
, vol.5
, Issue.11
-
-
Wang, Z.1
Zhang, C.2
Liu, X.3
Wang, Z.4
Sun, L.5
Li, G.6
-
67
-
-
85013230631
-
PD-L1 expression and combined status of PD-L1/PD-1-positive tumor infiltrating mononuclear cell density predict prognosis in glioblastoma patients
-
Han J, Hong Y, Lee YS. PD-L1 expression and combined status of PD-L1/PD-1-positive tumor infiltrating mononuclear cell density predict prognosis in glioblastoma patients. J Pathol Transl Med. 2017 Jan;51(1):40–8.
-
(2017)
J Pathol Transl Med
, vol.51
, Issue.1
, pp. 40-48
-
-
Han, J.1
Hong, Y.2
Lee, Y.S.3
-
68
-
-
84879484111
-
Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages
-
COI: 1:CAS:528:DC%2BC3sXpsVyns7o%3D, PID: 23613317
-
Bloch O, Crane CA, Kaur R, Safaee M, Rutkowski MJ, Parsa AT. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res. 2013;19(12):3165–75.
-
(2013)
Clin Cancer Res
, vol.19
, Issue.12
, pp. 3165-3175
-
-
Bloch, O.1
Crane, C.A.2
Kaur, R.3
Safaee, M.4
Rutkowski, M.J.5
Parsa, A.T.6
-
69
-
-
84892866206
-
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma
-
COI: 1:CAS:528:DC%2BC3sXhvF2kur7L, PID: 24145345
-
Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013;31(34):4311–8.
-
(2013)
J Clin Oncol
, vol.31
, Issue.34
, pp. 4311-4318
-
-
Weber, J.S.1
Kudchadkar, R.R.2
Yu, B.3
Gallenstein, D.4
Horak, C.E.5
Inzunza, H.D.6
-
70
-
-
84891534246
-
Programmed death ligand-1 expression in non-small cell lung cancer
-
COI: 1:CAS:528:DC%2BC3sXhslygs7jJ, PID: 24217091
-
Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Investig. 2014;94(1):107–16.
-
(2014)
Lab Investig
, vol.94
, Issue.1
, pp. 107-116
-
-
Velcheti, V.1
Schalper, K.A.2
Carvajal, D.E.3
Anagnostou, V.K.4
Syrigos, K.N.5
Sznol, M.6
-
71
-
-
84948451779
-
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
-
COI: 1:CAS:528:DC%2BC2MXhvFamtL3K, PID: 26541606
-
Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084–9.
-
(2015)
Science
, vol.350
, Issue.6264
, pp. 1084-1089
-
-
Sivan, A.1
Corrales, L.2
Hubert, N.3
Williams, J.B.4
Aquino-Michaels, K.5
Earley, Z.M.6
-
72
-
-
84948461699
-
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
-
COI: 1:CAS:528:DC%2BC2MXhvFamtL3J, PID: 26541610
-
Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079–84.
-
(2015)
Science
, vol.350
, Issue.6264
, pp. 1079-1084
-
-
Vetizou, M.1
Pitt, J.M.2
Daillere, R.3
Lepage, P.4
Waldschmitt, N.5
Flament, C.6
-
73
-
-
80051693219
-
Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide
-
COI: 1:CAS:528:DC%2BC3MXhtVajs7fK, PID: 21737504
-
Grossman SA, Ye X, Lesser G, Sloan A, Carraway H, Desideri S, et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res. 2011;17(16):5473–80.
-
(2011)
Clin Cancer Res
, vol.17
, Issue.16
, pp. 5473-5480
-
-
Grossman, S.A.1
Ye, X.2
Lesser, G.3
Sloan, A.4
Carraway, H.5
Desideri, S.6
-
74
-
-
0028917333
-
Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas
-
COI: 1:STN:280:DyaK2M3ktVansw%3D%3D, PID: 7723496
-
Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group Lancet. 1995;345(8956):1008–12.
-
(1995)
The Polymer-brain Tumor Treatment Group Lancet
, vol.345
, Issue.8956
, pp. 1008-1012
-
-
Brem, H.1
Piantadosi, S.2
Burger, P.C.3
Walker, M.4
Selker, R.5
Vick, N.A.6
-
75
-
-
84873129162
-
The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells
-
COI: 1:CAS:528:DC%2BC3sXhvFGqsr0%3D
-
Yovino S, Kleinberg L, Grossman SA, Narayanan M, Ford E. The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells. Cancer Investig. 2013;31(2):140–4.
-
(2013)
Cancer Investig
, vol.31
, Issue.2
, pp. 140-144
-
-
Yovino, S.1
Kleinberg, L.2
Grossman, S.A.3
Narayanan, M.4
Ford, E.5
-
76
-
-
0017804612
-
Analysis of treatment in childhood leukemia. IV. The critical association between dose fractionation and immunosuppression induced by cranial irradiation
-
COI: 1:STN:280:DyaE1c7gsFSrtQ%3D%3D, PID: 272224
-
MacLennan IC, Kay HE. Analysis of treatment in childhood leukemia. IV. The critical association between dose fractionation and immunosuppression induced by cranial irradiation. Cancer. 1978;41(1):108–11.
-
(1978)
Cancer
, vol.41
, Issue.1
, pp. 108-111
-
-
MacLennan, I.C.1
Kay, H.E.2
-
77
-
-
67649966553
-
Site-specific anti-tumor immunity: differences in DC function, TGF-beta production and numbers of intratumoral Foxp3+ Treg
-
COI: 1:CAS:528:DC%2BD1MXltlegtbo%3D, PID: 19337997
-
Biollaz G, Bernasconi L, Cretton C, Puntener U, Frei K, Fontana A, et al. Site-specific anti-tumor immunity: differences in DC function, TGF-beta production and numbers of intratumoral Foxp3+ Treg. Eur J Immunol. 2009;39(5):1323–33.
-
(2009)
Eur J Immunol
, vol.39
, Issue.5
, pp. 1323-1333
-
-
Biollaz, G.1
Bernasconi, L.2
Cretton, C.3
Puntener, U.4
Frei, K.5
Fontana, A.6
-
78
-
-
73149092567
-
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria
-
COI: 1:CAS:528:DC%2BD1MXhsFSnu7vN, PID: 19934295
-
Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–20.
-
(2009)
Clin Cancer Res
, vol.15
, Issue.23
, pp. 7412-7420
-
-
Wolchok, J.D.1
Hoos, A.2
O'Day, S.3
Weber, J.S.4
Hamid, O.5
Lebbe, C.6
-
79
-
-
84960956996
-
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
-
PID: 26545842
-
Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015;16(15):e534–42.
-
(2015)
Lancet Oncol
, vol.16
, Issue.15
, pp. e534-e542
-
-
Okada, H.1
Weller, M.2
Huang, R.3
Finocchiaro, G.4
Gilbert, M.R.5
Wick, W.6
|